Companies Cryptocurrencies
Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc
Exchange: NasdaqGM
IPO Date: 09/11/2018
CEO: Mr. Sean E. Brynjelsen
Biotechnology Healthcare 🔗
  • ETON
  • 5.63
  • 138499136
    market cap
  • -0.02999973
If you bought

shares of Eton Pharmaceuticals Inc (ETON) on
You would have made
Old Price $12 Current Price $12

Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 11 full-time employees. The company products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The firm focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.

Address: 21925 W Field Pkwy Ste 235 Deer Park ILLINOIS 60010-7208

Stay updated.